BR0213292A - tratamento de pneumonia severa por administração de inibidor da via de fator tecidual (tfpi) - Google Patents
tratamento de pneumonia severa por administração de inibidor da via de fator tecidual (tfpi)Info
- Publication number
- BR0213292A BR0213292A BRPI0213292-3A BR0213292A BR0213292A BR 0213292 A BR0213292 A BR 0213292A BR 0213292 A BR0213292 A BR 0213292A BR 0213292 A BR0213292 A BR 0213292A
- Authority
- BR
- Brazil
- Prior art keywords
- tfpi
- administration
- tissue factor
- treatment
- severe pneumonia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Abstract
"TRATAMENTO DE PNEUMONIA SEVERA POR ADMINISTRAçãO DE INIBIDOR DA VIA DE FATOR TECIDUAL (TFPI)". Métodos para tratar profilaticamente ou terapeuticamente pneumonia severa envolvem a administração de inibidor da via de fator tecidual (TFPI) ou um análogo de TFPI a pacientes que sofrem de ou em risco de desenvolver essa condição. Os métodos envolvem o uso de infusão intravenosa contínua de TFPI ou de um análogo de TFPI, preferivelmente em doses baixas para evitar efeitos colaterais adversos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32880601P | 2001-10-15 | 2001-10-15 | |
PCT/US2002/032624 WO2003032904A2 (en) | 2001-10-15 | 2002-10-15 | Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi) |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0213292A true BR0213292A (pt) | 2006-05-23 |
Family
ID=23282520
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0213292-3A BR0213292A (pt) | 2001-10-15 | 2002-10-15 | tratamento de pneumonia severa por administração de inibidor da via de fator tecidual (tfpi) |
BR0213293-1A BR0213293A (pt) | 2001-10-15 | 2002-10-15 | Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0213293-1A BR0213293A (pt) | 2001-10-15 | 2002-10-15 | Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia |
Country Status (17)
Country | Link |
---|---|
US (2) | US7674769B2 (pt) |
EP (2) | EP1446140A4 (pt) |
JP (5) | JP2005515214A (pt) |
KR (2) | KR20040040489A (pt) |
CN (2) | CN1604787A (pt) |
AU (2) | AU2002365131B2 (pt) |
BR (2) | BR0213292A (pt) |
CA (2) | CA2463655A1 (pt) |
EA (2) | EA200400549A1 (pt) |
HU (2) | HUP0500472A2 (pt) |
IL (2) | IL161408A0 (pt) |
IS (2) | IS7224A (pt) |
MX (2) | MXPA04003547A (pt) |
NO (2) | NO20041996D0 (pt) |
PL (2) | PL372138A1 (pt) |
WO (2) | WO2003032904A2 (pt) |
ZA (2) | ZA200403601B (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL372138A1 (en) | 2001-10-15 | 2005-07-11 | Chiron Corporation | Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi) |
EP1589949B1 (en) * | 2003-01-08 | 2008-08-13 | Novartis Vaccines and Diagnostics, Inc. | Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants |
EP1654283B1 (en) | 2003-08-13 | 2011-07-13 | Novartis Vaccines and Diagnostics, Inc. | Improved method of purifying tfpi and tfpi analogs |
RU2006136267A (ru) * | 2004-03-17 | 2008-04-27 | Чирон Корпорейшн (Us) | Лечение тяжелой внебольничной пневмонии путем введения ингибитора пути тканевого фактора (tfpi) |
CN101180074A (zh) * | 2005-04-15 | 2008-05-14 | 诺华疫苗和诊断公司 | 通过施用组织因子通路抑制剂(tfpi)治疗严重社区获得性肺炎 |
JP2008540460A (ja) * | 2005-05-06 | 2008-11-20 | ノバルティス アーゲー | 重症細菌感染を処置するためのtfpiの使用 |
CN101500607B (zh) | 2005-05-16 | 2013-11-27 | 阿布维生物技术有限公司 | TNFα抑制剂治疗腐蚀性多关节炎的用途 |
CN101262879B (zh) * | 2005-06-24 | 2013-04-10 | 德拉格雷丘尔公司 | 在影响呼吸道的炎症病状中气道施用活化的蛋白c |
KR20080040676A (ko) * | 2005-07-22 | 2008-05-08 | 노파르티스 아게 | 항미생물제로서의 tfpi 단편 |
US9624295B2 (en) | 2006-04-10 | 2017-04-18 | Abbvie Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
WO2009014633A1 (en) * | 2007-07-20 | 2009-01-29 | Trustees Of The University Of Pennsylvania | Method of treating acute respiratory distress syndrome |
WO2009129164A1 (en) * | 2008-04-15 | 2009-10-22 | Novartis Ag | Pharmaceutical combinations of tfpi-fragments and an antibiotic |
UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
WO2012078968A2 (en) | 2010-12-10 | 2012-06-14 | Lifeline Scientific, Inc. | Machine perfusion with complement inhibitors |
JP2014520873A (ja) | 2011-07-18 | 2014-08-25 | ザ ユニバーシティ オブ メルボルン | c−Fmsアンタゴニストの使用 |
KR101672108B1 (ko) | 2011-11-15 | 2016-11-02 | 아사히 가세이 파마 가부시키가이샤 | 패혈증의 치료 및/또는 개선을 위한 의약 |
KR20150140752A (ko) | 2013-04-12 | 2015-12-16 | 모르포시스 아게 | M-csf를 표적으로 하는 항체 |
US11908581B2 (en) | 2018-04-10 | 2024-02-20 | Hill-Rom Services, Inc. | Patient risk assessment based on data from multiple sources in a healthcare facility |
US11504071B2 (en) | 2018-04-10 | 2022-11-22 | Hill-Rom Services, Inc. | Patient risk assessment based on data from multiple sources in a healthcare facility |
WO2023142096A1 (en) * | 2022-01-30 | 2023-08-03 | Westlake University | Composition and method for preventing and/or treating clostridioides difficile infections caused by clade 2 strains |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4603106A (en) * | 1982-02-22 | 1986-07-29 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
JPS5896026A (ja) * | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
DE3219248A1 (de) | 1982-05-21 | 1983-11-24 | Solco Basel AG, Birsfelden | Verfahren zur gewinnung zellatmungsfoerdernder wirkstoffe aus kaelberblut |
US4609546A (en) * | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
US4620948A (en) * | 1982-12-22 | 1986-11-04 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4511502A (en) * | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4711845A (en) * | 1984-08-31 | 1987-12-08 | Cetus Corporation | Portable temperature-sensitive control cassette |
US4569790A (en) * | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
US4530787A (en) * | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
JPS61502166A (ja) | 1984-04-19 | 1986-10-02 | アグラシタス | 植物細胞の形質転換のための改良された方法及びベクタ− |
US4572798A (en) * | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
US4847201A (en) * | 1985-02-05 | 1989-07-11 | Cetus Corporation | DNA encoding for CSF-1 and accompanying recombinant systems |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4748234A (en) * | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
US5110730A (en) * | 1987-03-31 | 1992-05-05 | The Scripps Research Institute | Human tissue factor related DNA segments |
US5223427A (en) * | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
US4929700A (en) * | 1987-04-16 | 1990-05-29 | Cetus Corporation | Production of purified, biologically active, bacterially produced recombinant human CSF-1 |
US5106833A (en) * | 1987-07-23 | 1992-04-21 | Washington University | Coagulation inhibitors |
US4966852A (en) * | 1987-07-23 | 1990-10-30 | Monsanto Company | DNA clone of human tissue factor inhibitor |
IL87171A (en) | 1987-11-23 | 1995-08-31 | Monsanto Co | ANDC of human tissue factor inhibitor |
US5219994A (en) * | 1988-11-08 | 1993-06-15 | W. Alton Jones Cell Science Center, Inc. | Inhibitor of tissue factor activity |
DK412389D0 (da) | 1989-01-19 | 1989-01-19 | Novo Nordisk As | Fremgangsmaade til udvinding af oprenset epi protein fra en fermenteringsoploesning |
DK408089D0 (da) | 1989-08-18 | 1989-08-18 | Novo Nordisk As | Proteiner |
DK148890D0 (da) | 1990-06-19 | 1990-06-19 | Novo Nordisk As | Farmaceutisk praeparat |
IE913004A1 (en) | 1990-08-27 | 1992-03-11 | Monsanto Co | Anticoagulant combination of laci and sulfated¹polysaccharides |
US5506134A (en) | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
DK261490D0 (da) | 1990-10-31 | 1990-10-31 | Novo Nordisk As | New pharmaceutical compound |
US5212091A (en) * | 1992-03-02 | 1993-05-18 | Monsanto Company | Method of producing tissue factor pathway inhibitor |
US5276015A (en) | 1992-03-18 | 1994-01-04 | Washington University | Method of inhibiting microvascular thrombosis |
USRE36476E (en) | 1992-03-18 | 1999-12-28 | Washington University | Method of inhibiting microvascular thrombosis |
US6063764A (en) * | 1992-06-01 | 2000-05-16 | Washington University & Chiron Corp. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
JP3957740B2 (ja) | 1992-06-01 | 2007-08-15 | カイロン コーポレイション | 敗血症を治療するためにリポタンパク質関連凝集インヒビターを用いる方法 |
KR950701820A (ko) | 1992-06-11 | 1995-05-17 | 로저 에이. 윌리암스 | 패혈증 및 패혈증-연관 옹고장애의 예방 및 치료(prophylaxs and treatment of sepsis and sepsis-associated coagulation disorders) |
US5589359A (en) * | 1994-08-05 | 1996-12-31 | Chiron Corporation | Chimeric proteins |
JP3571378B2 (ja) * | 1994-09-30 | 2004-09-29 | 扶桑薬品工業株式会社 | 感染症診断用プローブ |
JP3761914B2 (ja) * | 1994-11-17 | 2006-03-29 | 財団法人化学及血清療法研究所 | アンチトロンビンiii及び組織因子凝固系インヒビター含有血栓症治療剤 |
US5914316A (en) | 1994-12-16 | 1999-06-22 | Washington University | Method of inhibiting intimal hyperplasia |
US5612363A (en) | 1995-06-02 | 1997-03-18 | Berlex Laboratories, Inc. | N,N-di(aryl) cyclic urea derivatives as anti-coagulants |
US6242414B1 (en) | 1995-06-07 | 2001-06-05 | Chiron Corporation | Regulation of cytokine synthesis and release |
US5888968A (en) | 1995-06-07 | 1999-03-30 | Chiron Corporation | TFPI formulation |
US5885781A (en) | 1995-06-07 | 1999-03-23 | Chiron Corporation | Regulation of cytokine synthesis and release |
DK1602667T3 (da) | 1995-06-07 | 2007-07-23 | Novartis Vaccines & Diagnostic | Vandig formulering omfattende TFPI og solubiliseringsmidler |
US5902582A (en) | 1995-09-05 | 1999-05-11 | Chiron Corporation | Use of TFPI inhibitor for treatment of cancer |
US5772629A (en) * | 1995-10-23 | 1998-06-30 | Localmed, Inc. | Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels |
US5736364A (en) | 1995-12-04 | 1998-04-07 | Genentech, Inc. | Factor viia inhibitors |
DE69726281T2 (de) | 1996-03-25 | 2004-08-26 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält |
US5977057A (en) * | 1996-05-08 | 1999-11-02 | The University Of Vermont And State Agricultural College | Thrombosis prophylaxis for factor VLEIDEN carriers |
WO1998033920A2 (en) * | 1997-01-31 | 1998-08-06 | Human Genome Sciences, Inc. | Tissue factor pathway inhibitor-3 |
US5981471A (en) * | 1997-02-06 | 1999-11-09 | Entremed, Inc. | Compositions and methods for inhibiting cellular proliferation |
HU224826B1 (en) | 1997-04-28 | 2006-02-28 | Lilly Co Eli | Activated protein c formulations |
IL121191A0 (en) | 1997-06-29 | 1997-11-20 | Yeda Res & Dev | Synthetic peptides and pharmaceutical compositions comprising them |
HUP0001237A3 (en) | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
US6824997B1 (en) * | 1998-09-18 | 2004-11-30 | Binax, Inc. | Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies |
CN1324244A (zh) | 1998-10-22 | 2001-11-28 | 伊莱利利公司 | 治疗脓毒症的方法 |
ES2195655T3 (es) | 1998-11-20 | 2003-12-01 | Lilly Co Eli | Procedimiento para tratar fiebre hemorragica virica con proteina c. |
AU4683299A (en) * | 1999-06-11 | 2001-01-02 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Detection of streptococcus pneumoniae and immunization against streptococcus pneumoniae infection |
JP2003530819A (ja) | 1999-06-14 | 2003-10-21 | ノボ ノルディスク アクティーゼルスカブ | FVIIa/TF活性阻害化合物 |
US6294648B1 (en) | 1999-07-20 | 2001-09-25 | Bayer Corporation | Protein having proteinase inhibitor activity |
US6180607B1 (en) | 1999-08-05 | 2001-01-30 | Christopher Davies | Protein having proteinase inhibitor activity |
HUP0203133A3 (en) | 1999-10-04 | 2005-07-28 | Chiron Corp Emeryville | Stabilized liquid polypeptide-containing pharmaceutical compositions |
EP1251868A1 (en) | 2000-01-06 | 2002-10-30 | Eli Lilly & Company | Combination therapy for the treatment of inflammatory and respiratory diseases |
EP1263943A1 (en) | 2000-02-11 | 2002-12-11 | Eli Lilly & Company | Protein c derivatives |
EP1267904A4 (en) | 2000-02-16 | 2006-02-08 | Univ Northwestern | POLYPEPTIDE PULMONAL TENSIDES |
DE10022092A1 (de) | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
US7015194B2 (en) | 2000-05-10 | 2006-03-21 | Novo Nordisk A/S | Pharmaceutical composition comprising factor VIIa and anti-TFPI |
WO2002102325A2 (en) | 2001-02-28 | 2002-12-27 | Griffin John H | Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein c |
WO2002099098A1 (en) | 2001-04-04 | 2002-12-12 | American Diagnostica, Inc | Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (tafi) and methods of use thereof |
DE10132307A1 (de) | 2001-07-06 | 2003-01-30 | Aventis Behring Gmbh | Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS |
PL372138A1 (en) | 2001-10-15 | 2005-07-11 | Chiron Corporation | Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi) |
US20020198138A1 (en) | 2002-06-07 | 2002-12-26 | Macias William Louis | Combination therapy for the treatment of inflammatory and respiratory diseases |
-
2002
- 2002-10-15 PL PL02372138A patent/PL372138A1/xx not_active Application Discontinuation
- 2002-10-15 JP JP2003556020A patent/JP2005515214A/ja not_active Withdrawn
- 2002-10-15 US US10/270,478 patent/US7674769B2/en not_active Expired - Fee Related
- 2002-10-15 KR KR10-2004-7005632A patent/KR20040040489A/ko not_active Application Discontinuation
- 2002-10-15 IL IL16140802A patent/IL161408A0/xx unknown
- 2002-10-15 CN CNA028250648A patent/CN1604787A/zh active Pending
- 2002-10-15 AU AU2002365131A patent/AU2002365131B2/en not_active Ceased
- 2002-10-15 KR KR1020047005618A patent/KR20050036867A/ko not_active Application Discontinuation
- 2002-10-15 WO PCT/US2002/032624 patent/WO2003032904A2/en not_active Application Discontinuation
- 2002-10-15 JP JP2003535710A patent/JP2005506345A/ja not_active Withdrawn
- 2002-10-15 MX MXPA04003547A patent/MXPA04003547A/es unknown
- 2002-10-15 CA CA002463655A patent/CA2463655A1/en not_active Abandoned
- 2002-10-15 PL PL02374506A patent/PL374506A1/xx not_active Application Discontinuation
- 2002-10-15 WO PCT/US2002/032625 patent/WO2003055442A2/en active IP Right Grant
- 2002-10-15 CN CNA028249003A patent/CN1604790A/zh active Pending
- 2002-10-15 HU HU0500472A patent/HUP0500472A2/hu unknown
- 2002-10-15 EA EA200400549A patent/EA200400549A1/ru unknown
- 2002-10-15 BR BRPI0213292-3A patent/BR0213292A/pt unknown
- 2002-10-15 IL IL16140702A patent/IL161407A0/xx unknown
- 2002-10-15 EP EP02778529A patent/EP1446140A4/en not_active Withdrawn
- 2002-10-15 CA CA002463738A patent/CA2463738A1/en not_active Abandoned
- 2002-10-15 HU HU0501111A patent/HUP0501111A2/hu unknown
- 2002-10-15 BR BR0213293-1A patent/BR0213293A/pt not_active Application Discontinuation
- 2002-10-15 EA EA200400548A patent/EA200400548A1/ru unknown
- 2002-10-15 AU AU2002340183A patent/AU2002340183B2/en not_active Ceased
- 2002-10-15 EP EP02803284A patent/EP1446138A4/en not_active Withdrawn
-
2003
- 2003-02-04 US US10/270,479 patent/US20030139340A1/en not_active Abandoned
-
2004
- 2004-04-15 IS IS7224A patent/IS7224A/is unknown
- 2004-04-15 MX MXPA04003548A patent/MXPA04003548A/es not_active Application Discontinuation
- 2004-04-15 IS IS7223A patent/IS7223A/is unknown
- 2004-05-11 ZA ZA200403601A patent/ZA200403601B/en unknown
- 2004-05-13 ZA ZA200403690A patent/ZA200403690B/xx unknown
- 2004-05-14 NO NO20041996A patent/NO20041996D0/no not_active Application Discontinuation
- 2004-05-14 NO NO20041997A patent/NO20041997D0/no not_active Application Discontinuation
-
2005
- 2005-09-16 JP JP2005271219A patent/JP2006008706A/ja active Pending
- 2005-09-16 JP JP2005271191A patent/JP2006008704A/ja not_active Withdrawn
-
2009
- 2009-10-09 JP JP2009235793A patent/JP2010006839A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0213292A (pt) | tratamento de pneumonia severa por administração de inibidor da via de fator tecidual (tfpi) | |
TNSN07413A1 (en) | Use of tfpi to treat severe bacterial infections | |
NO20051987L (no) | Behandling av soppinfeksjoner. | |
HUP0401998A2 (hu) | PDE9 inhibitorok alkalmazása olyan gyógyszer előállítására, amellyel inzulin-rezisztencia szindróma és 2-es típusú diabétesz kezelhető | |
KR930702022A (ko) | 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법 | |
CY1111088T1 (el) | Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση | |
BR0116370A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente. | |
EA200700232A1 (ru) | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения | |
BR9806060A (pt) | Composto, composição farmacêutica e processos para tratar um paciente sofrendo de um estado doentio, para inibir o fator xa, e, para inibir a formação de trombina. | |
BR0111591A (pt) | Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes | |
BR0211119A (pt) | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto | |
AR035927A1 (es) | Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr | |
MA27129A1 (fr) | Les pyrrolopyrimidines en tant qu'inhibiteurs du kinase de proteine. | |
BRPI0415953A (pt) | formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação | |
BR9709838A (pt) | Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase | |
BR0113590A (pt) | 7-oxo-piridopirimidinas | |
BR0210392A (pt) | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto | |
BR0005797A (pt) | Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados | |
BR0110913A (pt) | Método de administrar um bisfosfonato | |
BRPI0416882A (pt) | composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto | |
BR0212249A (pt) | Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto | |
WO1999045909A3 (en) | Use of nitrone compounds for the inhibition of angiogenesis | |
BRPI0508992A (pt) | tratamento de pneumonia severa pela administração de tfpi | |
IS8373A (is) | Notkun oxkarbasepíns til að meðhöndla sársauka vegna sykursýkisfjöltauga-kvilla og til að bæta svefn | |
BR0209985A (pt) | Composto e método para o tratamento de um paciente |